Affiliation:
1. Institute of Biomedical Chemistry, Moscow, Russia
Abstract
Isatin (indole-2,3-dione) is an endogenous regulator exhibiting various effects mediated by numerous isatin-binding proteins localized in different compartments of cells of the brain and peripheral tissues. It attenuates manifestations of experimental parkinsonism induced by administration of the MPTP neurotoxin and reduces the movement disorders characteristic of this disease. The molecular mechanisms of the neuroprotective action of isatin include its direct interaction with proteasomes, intracellular supramolecular complexes responsible for the targeted elimination of proteins. Incubation of fractions of 26S and 20S rabbit brain proteasomes, containing the whole spectrum of proteasomal subunits, as well as a number of proteasome-associated proteins, with isatin (100 μM) had a significant impact on the profile of released proteins. In the case of 26S proteasomes containing, in addition to the core part (20S proteasome), 19S regulatory subparticles, incubation with isatin resulted in a more than threefold increase in the number of dissociated proteins. In the case of 20S proteasomes (containing only the 20S core particle), incubation with isatin resulted in a significant decrease in the number of dissociated proteins compared to the control. Our results indicate an important role of the regulatory 19S subunit components in the formation of the proteasome subproteome and the sensitivity of these supramolecular complexes to isatin.
Publisher
Institute of Biochemistry
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference29 articles.
1. Medvedev A.E., Clow A., Sandler M., Glover V. (1996) Isatin − a link between natriuretic peptides and monoamines? Biochem. Pharmacol., 52, 385-391.
2. Medvedev A., Igosheva N., Crumeyrolle-Arias M., Glover V. (2005) Isatin: Role in stress and anxiety. Stress, 8, 175-183.
3. Medvedev A., Buneeva O., Glover V. (2007) Biological targets for isatin and its analogues: implications for therapy. Biologics, 1, 151-162.
4. Medvedev A., Buneeva O., Gnedenko O., Ershov P., Ivanov A. (2018) Isatin, an endogenous nonpeptide biofactor: A review of its molecular targets, mechanisms of actions, and their biomedical implications. Biofactors, 44(2), 95-108.
5. Medvedev A., Kopylov A., Buneeva O., Kurbatov L., Tikhonova O., Ivanov A., Zgoda V.A. (2020) Neuroprotective dose of isatin causes multilevel changes involving the brain proteome: Prospects for further research. Int. J. Mol. Sci., 21(11), 4187.